Alphamab Oncology (HK:9966) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Alphamab Oncology has presented promising research updates on its innovative drug, JSKN033, at SITC 2024, highlighting its potential in treating advanced HER2-expressing solid tumors. The phase I/II clinical trial showed an 80% disease control rate, with a favorable safety profile among the participants. This advancement underscores Alphamab’s progress in developing cutting-edge cancer therapies, potentially boosting investor confidence in its stock.
For further insights into HK:9966 stock, check out TipRanks’ Stock Analysis page.